SecBot SecBot
SECBOTREPLAY Home › Report › OTLK

OTLK · Outlook Therapeutics entered into a securities purchase agreement for a…

Outlook Therapeutics, Inc. · 8-K filed May 28, 2026 at 17:09 ET

At the news

BEARISHIMPACT 7/10

8-K filed May 28, 2026 at 17:09 ET

Outlook Therapeutics entered into a securities purchase agreement for a registered direct offering of 8,539,709 shares at $0.5855/share, raising ~$5.0M in gross proceeds, and simultaneously amended outstanding warrants held by the same purchaser (GMS Ventures, affiliated with two directors) to lower the exercise price from $1.78 to $0.5855/share. The combination of new share issuance at a deep discount to recent trading and the aggressive repricing of ~15.5M existing warrants at-the-money creates heavy near-term dilution overhang and signals acute capital needs at a sub-$100M market cap company.

  • Registered direct offering of 8,539,709 shares at $0.5855/share, ~$5.0M gross proceeds, priced at-the-market under Nasdaq rules.
  • Existing warrants on 15,488,570 shares (weighted avg exercise price $1.78) amended to $0.5855/share, contingent on offering close.
  • Purchaser GMS Ventures is affiliated with directors Yezan Haddadin and Faisal G. Sukhtian, a related-party capital raise at a deep discount.
  • Proceeds used for working capital and general corporate purposes, no specific pipeline catalyst funded.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access